Organogenesis (NASDAQ:ORGO) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Organogenesis from “strong sell” to “sell,” while the broader analyst consensus remains “Reduce” with an average price target of $4.33.
• Organogenesis reported a significant quarterly miss, posting an adjusted loss of $0.71 per share versus the $0.35 consensus estimate and revenue of $43.76 million versus expectations of $54.27 million.
• ORGO shares opened at $1.42, near their 12-month low of $1.34, with a market capitalization of approximately $182.7 million; institutional investors own about 49.6% of the stock.

Organogenesis (NASDAQ:ORGO - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on the company. Truist Financial cut their price target on Organogenesis from $3.00 to $2.00 and set a "hold" rating for the company in a report on Friday, August 7th. Weiss Ratings lowered Organogenesis from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, September 4th. Finally, UBS Group set a $3.00 price objective on Organogenesis in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $4.33.

Organogenesis Stock Up 4.4%

ORGO stock opened at $1.42 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. The company's 50 day simple moving average is $1.98 and its 200-day simple moving average is $2.30. Organogenesis has a 12 month low of $1.34 and a 12 month high of $7.08. The firm has a market capitalization of $182.73 million, a PE ratio of -1.65 and a beta of 1.29.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.The company had revenue of $43.76 million for the quarter, compared to analyst estimates of $54.27 million.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Organogenesis in the second quarter valued at $17,616,000. Dimensional Fund Advisors LP lifted its position in Organogenesis by 5.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company's stock worth $6,851,000 after buying an additional 160,026 shares during the period. Deutsche Bank AG acquired a new stake in Organogenesis in the 2nd quarter worth about $4,146,000. Renaissance Technologies LLC boosted its stake in Organogenesis by 30.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company's stock worth $2,532,000 after buying an additional 249,838 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in Organogenesis by 39.8% in the 1st quarter. SG Americas Securities LLC now owns 790,766 shares of the company's stock worth $1,874,000 after buying an additional 225,265 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company focused on regenerative medicine products for wound care, surgical procedures and sports medicine. The company develops and commercializes biologically derived products designed to support tissue repair and healing.

Its advanced wound care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as products such as Dermagraft, Affinity, NuShield and other wound coverings and tissue matrices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.